{"id":"epirubicin-pirarubicin-hydroxycamptothecin-and-fluorouracil","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Myelosuppression"},{"rate":"5-15%","effect":"Cardiotoxicity"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL417","moleculeType":"Small molecule","molecularWeight":"543.53"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Epirubicin and pirarubicin are anthracyclines that intercalate DNA strands, inhibiting the enzyme topoisomerase II and inducing DNA damage. Fluorouracil is an antimetabolite that inhibits thymidylate synthase, leading to the accumulation of toxic metabolites and DNA damage. Hydroxycamptothecin is a topoisomerase I inhibitor that blocks the enzyme's ability to repair DNA damage, leading to cell death.","oneSentence":"Epirubicin, pirarubicin, and fluorouracil are anthracycline and antimetabolite chemotherapeutic agents that work by inhibiting DNA synthesis and inducing DNA damage, leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:11.907Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Metastatic colorectal cancer"},{"name":"Metastatic gastric cancer"}]},"trialDetails":[{"nctId":"NCT02755311","phase":"PHASE3","title":"Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2014-03","conditions":"Hepatocellular Carcinoma","enrollment":198}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["epirubicin，pirarubicin，hydroxycamptothecin or fluorouracil"],"phase":"phase_3","status":"active","brandName":"epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil","genericName":"epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epirubicin, pirarubicin, and fluorouracil are anthracycline and antimetabolite chemotherapeutic agents that work by inhibiting DNA synthesis and inducing DNA damage, leading to cell death. Used for Metastatic breast cancer, Metastatic colorectal cancer, Metastatic gastric cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}